{
 "name": "麗寶新藥",
 "slug": "tw-7888",
 "aliases": [
  "麗寶新藥生物科技股份有限公司",
  "LIBO",
  "7888"
 ],
 "ticker": "7888",
 "industry": "生技醫療業",
 "website": "https://libopharma.com/",
 "summary": "麗寶新藥（7888）是興櫃的生技醫療類股公司，2017 年成立，2025 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "麗寶新藥生物科技股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "LIBO",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2025-12-23",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2017-01-26",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "杜德成",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "劉朝瀚",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 752350000,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "https://libopharma.com/",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：LIB-101-HSARS（rHuIL-12）",
   "value": "造血相關急性輻射症候群｜第二期完成｜全球授權地區（歐洲、美國、以色列除外）",
   "unit": "",
   "as_of": "2026-05-25",
   "source": "https://libopharma.com/wp-content/uploads/2026/06/114年股東會-股東會年報.pdf",
   "note": "年報印刷頁49；地區欄依授權範圍，不宣稱在所有地區均已完成試驗。"
  },
  {
   "claim": "管線：LIB-101-CTCL（rHuIL-12）",
   "value": "皮膚T細胞淋巴瘤｜第IIa期完成，規劃第2b/3期｜全球",
   "unit": "",
   "as_of": "2026-05-25",
   "source": "https://libopharma.com/wp-content/uploads/2026/06/114年股東會-股東會年報.pdf",
   "note": "年報印刷頁49及致股東報告。"
  },
  {
   "claim": "管線：LIB-101-DLBCL（rHuIL-12）",
   "value": "瀰漫性大B細胞淋巴瘤｜第二期進行中｜台灣、美國（規劃收案）",
   "unit": "",
   "as_of": "2026-05-25",
   "source": "https://libopharma.com/wp-content/uploads/2026/06/114年股東會-股東會年報.pdf",
   "note": "年報印刷頁49-50，規劃兩地收案，未宣稱兩地均已實際開站。"
  },
  {
   "claim": "催化劑：LIB-101-CTCL",
   "value": "啟動全球第2b/3期多國多中心試驗｜2026（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-05-25",
   "source": "https://libopharma.com/wp-content/uploads/2026/06/114年股東會-股東會年報.pdf",
   "note": "年報致股東報告書；未有更精確日期，亦未查得截至查核日啟動完成之新公告。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-7888.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}